Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12715761 | 0.87 | KCNA5 (0.44) | KCNA5PDPK1MAPK14KDM4AALOX5AP | |
| SCHEMBL1617129 | 0.86 | MAPK14 (0.55) | KCNA5PDPK1MAPK14KDM4A | |
| SCHEMBL1617184 | 0.85 | MAPK14 (0.55) | KCNA5MAPK14 | |
| SCHEMBL12715760 | 0.84 | KCNA5 (0.41) | KCNA5PDPK1MAPK14KDM4AALOX5AP | |
| SCHEMBL12715763 | 0.84 | MAPK14 (0.59) | KCNA5PDPK1MAPK14KDM4AALOX5AP | |
| SCHEMBL1617350 | 0.80 | MAPK14 (0.36) | MAPK14 | |
| SCHEMBL12715438 | 0.76 | MAPK14 (0.52) | KCNA5PDPK1MAPK14KDM4AALOX5AP | |
| SCHEMBL1615771 | 0.74 | MAPK14 (0.54) | KCNA5MAPK14ALOX5APFEN1 | |
| SCHEMBL4408144 | 0.74 | MAPK14 (0.56) | KCNA5PDPK1MAPK14KDM4A | |
| SCHEMBL12715895 | 0.73 | MAPK14 (0.62) | KCNA5MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| EP-1848714-B1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | LIMK1, LIMK2, MAPK1 | KCNA5 3251/4885PDPK1 116/4885MAPK14 83/4885 |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | LIMK1, LIMK2, MAPK1 | KCNA5 3251/4885PDPK1 116/4885MAPK14 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.